Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors

Basit Öğe Kaydı
dc.contributor.authorGenc, Selin
dc.contributor.authorEvren, Bahri
dc.contributor.authorYigit, Onur Selcuk
dc.contributor.authorSahin, Ibrahim
dc.contributor.authorDayanan, Ramazan
dc.contributor.authorKlisic, Aleksandra
dc.contributor.authorErturk, Ayse
dc.date.accessioned2026-04-04T13:30:59Z
dc.date.available2026-04-04T13:30:59Z
dc.date.issued2024
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground/Objectives: The antidiabetic effect of SGLT2 inhibitors (SGLT2-is) is based on their ability to increase glucose excretion through urine by inhibiting the kidney-resident SGLT2 protein. Euglycemic diabetic ketoacidosis (EuDKA) is an uncommon but potentially life-threatening adverse effect of these medications, which are notable for their antidiabetic, cardiovascular, and renal protective properties. This study aimed to clarify the impact of SGLT2-is on demographic, clinical, and biochemical characteristics in patients with DKA. Methods: A total of 51 individuals with a diagnosis of DKA were included in the trial; 19 of these patients were treated with SGLT2-is, while 32 were not. Patients diagnosed with DKA and treated with SGLT2-is were compared to those not treated with the medication in terms of clinical, biochemical, and laboratory characteristics. Results: The age of patients utilizing SGLT2-is was statistically considerably greater than that of non-users (p < 0.001). EuDKA was exclusively noted in the SGLT2-is cohort (p = 0.005). Urinary tract infections, vulvovaginitis, and genitourinary infections were substantially more prevalent among SGLT2-i users compared with non-users among both women and the overall patient group (p = 0.036, p = 0.001, p = 0.005, p = 0.003, respectively). Plasma glucose concentrations were significantly higher in SGLT2-i non-users (p = 0.006). Chloride (Cl-) concentrations were elevated among SGLT2-i users (p = 0.036). Conclusions: The study findings indicate that SGLT2 inhibitors may substantially influence age, serum chloride, EuDKA, and the occurrence of genitourinary infections in individuals with DKA.
dc.description.sponsorshipThe Recep Tayyip Erdogan University Development Foundation [02024007031026] Funding Source: Medline
dc.identifier.doi10.3390/ph17111553
dc.identifier.issn1424-8247
dc.identifier.issue11
dc.identifier.orcid0000-0002-8510-3046
dc.identifier.orcid0000-0002-4325-1534
dc.identifier.orcid0000-0001-6413-9165
dc.identifier.orcid0000-0001-7870-0996
dc.identifier.pmid39598463
dc.identifier.scopus2-s2.0-85210438281
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/ph17111553
dc.identifier.urihttps://hdl.handle.net/11616/108492
dc.identifier.volume17
dc.identifier.wosWOS:001367145700001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofPharmaceuticals
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectdiabetic ketoacidosis (DKA)
dc.subjecteuglycemic diabetic ketoacidosis (euDKA)
dc.subjectgenitourinary infection (GUI)
dc.subjectlatent autoimmune diabetes in adults (LADA)
dc.subjectsodium-glucose co-transporter-2 inhibitor (SGLT2-i)
dc.subjecttype 1 diabetes mellitus (T1DM)
dc.titleEvolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu